Objective
The goal of the T1D Cures Accelerator (T1DCA) is to bring together experts from academia, industry, and nonprofit organizations in a neutral, collaborative partnership to speed progress toward better treatments and cures for type 1 diabetes (T1D). By creating a trusted consortium with clear rules and shared goals, T1DCA allows participants to work together in ways that would not be possible within individual institutions or single clinical trials.
A central objective of the project is to identify biological markers—called biomarkers—that can show how the disease is progressing or whether a treatment is working. Today, many clinical trials for T1D take years to complete and often provide unclear results, partly because there are few reliable ways to measure early treatment effects or predict who will benefit from a therapy. T1DCA addresses this problem by combining data and samples from multiple completed trials and analyzing them together using consistent methods. This approach makes it easier to spot meaningful biological patterns that individual studies are too small to detect on their own.
Another important objective of T1DCA is to ensure that biomarker discoveries are useful in the real world. Finding a potential biomarker is not enough—researchers, clinicians, and regulators need to agree on what it measures, when it should be used, and how it can improve clinical trials. By involving key stakeholders early and working toward shared standards, T1DCA helps lay the groundwork for biomarkers that can be adopted broadly and used to improve future studies.
Finally, T1DCA is designed to grow over time. While the initial effort focuses on a defined set of trials and analyses, the consortium establishes the structure needed to expand to additional studies, technologies, and partners in the future. This scalable approach ensures that the benefits of the project extend beyond the current work, creating a lasting resource to support more efficient clinical trials, better‑targeted therapies, and ultimately improved outcomes for people living with type 1 diabetes.
Background Rationale
Despite decades of research, type 1 diabetes (T1D) remains a disease without a cure. Numerous clinical trials have tested therapies designed to modify the immune system and preserve insulin production, and some have shown modest success. However, translating these results into durable, widely effective treatments has been slow. A key barrier to progress is the absence of robust biomarkers – biological indicators that can track disease activity, predict treatment response, or serve as early signs that a therapy is working.
Most T1D clinical trials rely on long term outcomes, such as insulin production measured over multiple years. These endpoints make trials lengthy, expensive, and risky. In addition, individuals with T1D vary widely in age, immune profile, genetics, and disease progression, making it difficult to detect consistent treatment effects in small or moderate sized studies. As a result, potentially effective therapies may be abandoned before their full value is understood.
At the same time, modern clinical trials have produced rich collections of biological samples from both those who respond to therapies and those who don’t. Advances in laboratory technologies now allow thousands of genes or proteins to be measured from a single blood sample. When analyzed properly, these data can reveal immune pathways, cell types, and molecular signatures associated with disease progression or therapeutic response. However, these opportunities are often missed because samples and data remain siloed within individual trials or organizations.
The T1D Cures Accelerator (T1DCA) was created to address this gap. Its rationale is straightforward: combining data and samples from multiple trials, analyzing them in a harmonized manner, and applying advanced analytical tools will greatly increase the chances of identifying meaningful, reproducible biomarkers. Such an approach has already proven effective in other contexts, where cross trial analyses revealed important links between biological markers and clinical outcomes that were not apparent in single studies.
Equally important is the collaborative, precompetitive structure of T1DCA. Biomarker development requires alignment across academia, industry, and regulatory bodies. By establishing shared standards, governance, and analytical frameworks, T1DCA ensures that biomarker discoveries are not only scientifically sound but also positioned for future use in clinical trials and regulatory decision making. This integrated strategy provides a strong scientific and practical rationale for the project and underpins its potential to accelerate progress toward better treatments and cures for T1D.
Description of Project
Type 1 diabetes (T1D) is a lifelong autoimmune disease that affects millions of children and adults worldwide. While current treatments manage blood sugar, they do not address the underlying causes of disease or stop its progression. Over the past decade, multiple clinical trials have tested immune-based therapies that can slow the loss of insulin producing cells, but progress toward cures has been limited. One major reason is the lack of reliable biological markers—called biomarkers—that can be an early indicator of a working therapy, identify which patients are most likely to benefit, or explain why some treatments succeed while others fail.
The T1D Cures Accelerator (T1DCA) is a multi-institutional, multi-sector research initiative designed to address this challenge. The project brings together academic researchers, clinicians, industry partners, and foundations in a coordinated effort focused on discovering biomarkers of disease progression and treatment response in T1D. Rather than conducting a single new clinical trial, T1DCA integrates data and biological samples from many existing trials, including studies with positive and negative outcomes.
By combining information across trials, the project enables researchers to identify biological patterns that are not visible in individual studies. These patterns include signals from the immune system, genetic factors and other measures that may predict how a person’s disease will evolve or how they respond to therapy. T1DCA applies modern scientific approaches using standardized methods and shared definitions and ensures that results are comparable across studies and reflect true biological differences.A key feature of the project is its governance structure, which ensures transparency, fairness, and responsible data use. A steering committee provides scientific oversight, while specialized working groups conduct the science. The consortium is housed and administered by an experienced nonprofit organization with a long history of managing complex scientific collaborations.
Ultimately, the T1D Cures Accelerator aims to transform how T1D therapies are developed and tested. By creating a shared resource of high quality, harmonized data and confirmed biomarkers, the project seeks to shorten clinical trials, reduce costs, improve patient selection, and accelerate the path toward effective disease modifying treatments and, ultimately, cures.
Anticipated Outcome
The T1D Cures Accelerator (T1DCA) is expected to generate outcomes that significantly advance both scientific understanding and therapeutic development for type 1 diabetes (T1D). In the near term, the project will produce a harmonized, high-quality dataset that integrates clinical information and biological measurements from multiple trials. This resource will enable researchers to examine disease mechanisms and treatment responses across a scale that is not possible within individual studies.
One anticipated outcome is the identification of biomarkers that reliably reflect therapeutic response and disease progression. These biomarkers may include immune signatures, protein patterns, or molecular pathways associated with preservation of insulin production. Biomarkers can serve multiple roles: identifying patients most likely to benefit from a therapy, reducing variability in clinical trials, and detecting treatment effects earlier than current clinical endpoints.
Another key outcome is improved understanding of why some therapies succeed while others do not. By comparing biological responses across trials with different mechanisms of action, stages of disease, and dosing strategies, T1DCA can uncover shared and distinct pathways that drive success or failure. These insights can guide future drug development, inform combination therapies, and help avoid repeating ineffective approaches.
Over the longer term, T1DCA is expected to influence how clinical trials in T1D are designed and conducted. The availability of standardized, regulatory ready biomarkers could shorten trial duration, reduce costs, and make trials more efficient and informative. This would lower barriers for testing new therapies and encourage greater investment in disease modifying treatments.
Finally, the project is anticipated to leave a lasting legacy beyond its initial analyses. Through its collaborative model, governance framework, and commitment to data sharing, T1DCA will establish a platform that can continue to grow, incorporate new technologies, and support future trials. By aligning scientific discovery with clinical and regulatory needs, the accelerator aims to move the field closer to precision medicine approaches and, ultimately, to therapies that change the course of T1D for patients and families.
Relevance to T1D
Type 1 diabetes (T1D) is a complex autoimmune disease in which the immune system mistakenly attacks the insulin‑producing cells of the pancreas. Unlike many chronic conditions, T1D typically begins early in life and requires continuous treatment for survival. Although insulin therapy has transformed outcomes, it does not address the underlying disease process, and people with T1D remain at risk for serious complications and reduced quality of life. Developing therapies that can slow, stop, or prevent T1D progression remains an urgent unmet need.
In recent years, several clinical trials have tested immune‑modifying therapies that can partially preserve insulin production or delay disease onset. These trials demonstrate that disease modification is possible, but their effects are often modest and variable across individuals. Some people benefit substantially, while others show little or no response. For patients, families, clinicians, and developers, this uncertainty makes it difficult to choose the right therapy, design efficient trials, or move promising treatments forward.
The T1D Cures Accelerator (T1DCA) directly addresses this challenge by focusing on biomarkers—measurable biological signals that reflect disease activity and response to treatment. Reliable biomarkers could transform T1D research and care by identifying which individuals are most likely to benefit from a given therapy, detecting therapeutic effects earlier, and revealing why treatments succeed or fail. This is particularly important in T1D, where trials can last years and require large numbers of participants to demonstrate benefit.
T1DCA is highly relevant to the T1D community because it leverages an asset that already exists: data and biological samples from multiple completed and ongoing clinical trials. Rather than starting from scratch, the project integrates these resources across studies and organizations, creating a unified framework for discovery. By analyzing samples from people at different disease stages and with different treatment outcomes, T1DCA captures the biological diversity that defines T1D.
Importantly, the project examines both immune system activity and markers of pancreatic beta‑cell health. This dual focus reflects the reality of T1D as a disease driven by immune attack with metabolic consequences. Understanding how these processes interact over time is essential for developing therapies that meaningfully alter disease course.
The relevance of T1DCA extends beyond discovery alone. By engaging clinicians, researchers, industry partners, and regulators early, the project ensures that identified biomarkers are positioned for real‑world use in clinical trials and, eventually, patient care. This approach increases the likelihood that discoveries will translate into shorter, more informative trials, improved treatment strategies, and better outcomes for people with T1D.
Ultimately, by accelerating biomarker discovery, the T1D Cures Accelerator aims to change how T1D therapies are developed and evaluated—bringing the field closer to effective disease‑modifying treatments and, ultimately, cures.